The FLAURA phase 3 trial of osimertinib vs gefitinib in first line also showed a shorter PFS and OS in EGFR‐mutant NSCLC harboring the L858R mutation in tumor tissue [88, 89]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.